Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Azstarys in children with ADHD
NCT03460652Phase 3Completed
- Sponsor
- Zevra Therapeutics
- Start
- Mar 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of serdexmethylphenidate + dexmethylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Zevra Therapeutics. Started Mar 2018; status: completed.
02
Drugs
serdexmethylphenidate + dexmethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03460652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03460652.